Beneficial antithrombotic effects of the association of pharmacological oral magnesium therapy with aspirin in coronary heart disease patients.

What Was Tested

The paper reports a study of Magnesium and Aspirin, published as a randomized controlled trial.

The aim of their study was to determine whether oral magnesium treatment inhibits platelet-dependent thrombosis (PDT) in stable patients with coronary artery disease (CAD).

Who Took Part

The abstract describes 42 patients taking part.

The age groups tagged for this paper are middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Magnesium and who got the comparison, which limits bias.

Blinding on both sides kept the patients and researchers unaware of who received Magnesium.

A placebo (an inactive look-alike) gave the Magnesium group a baseline to be compared against.

In the crossover set-up each of the patients took both Magnesium and the comparison in turn, acting as their own control.

PDT, platelet aggregation, platelet P-selectin flow-cytometry, monocyte tissue factor procoagulant activity (TF-PCA) and adhesion molecules density were assessed before and after each phase.

PDT was evaluated by an ex-vivo perfusion model using the Badimon chamber.

What Was Measured

Topics PubMed links to this paper include Aspirin, Cell Adhesion, Cholesterol, HDL, Cholesterol, LDL, Cholesterol, VLDL, Coronary Disease and Electrolytes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Magnesium and Aspirin in 42 patients.

The publication is from 2000 (Magnesium research), a journal based in England.

More context: the related Vitamin D, K2, Magnesium and Zinc library page, all human trials.